First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia Our study demonstrated that ...
Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years ...
Acute myeloid leukemia (AML) is a type of cancer that begins in the blood-forming cells of the bone marrow. Doctors do not stage AML like many other cancers, as it does not typically form tumors.
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
Treatment of older patients with AML involves complex decisions taking into consideration age, fitness, treatment tolerability, quality of life, and social support. Increased treatment options have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results